-
1: Trial Name : TORRENT - 2017 - 2021
Sponsor: IQVIA RDS India Pvt Ltd
Title: A Phase III randomized, double blind , parallel group placebo controlled, multi- centre. Multinational study to evaluate efficacy and safety of TRC 150094 as an add on to standard of care in improving cardiovascular risk in subjects with diabetes, dyslipidaemia and hypertension.
-
2. Trial Name : PIONEER 6 - 2017 - 2019
Sponsor: Novo Nordisk
Title: A trial investigating the cardiovascular safety of oral Semaglutide in subjects with Type 2 diabetes
-
3. Trial Name: STEP -1 - 2018 - 2020
Sponsor: Novo Nordisk
Title : Effect and safety of Semaglutide 2.4 mg once weekly in subjects with overweight or obesity.
Indication: Obesity
